HK1027377A1 - Lage-3 splice variants. - Google Patents

Lage-3 splice variants.

Info

Publication number
HK1027377A1
HK1027377A1 HK00106456A HK00106456A HK1027377A1 HK 1027377 A1 HK1027377 A1 HK 1027377A1 HK 00106456 A HK00106456 A HK 00106456A HK 00106456 A HK00106456 A HK 00106456A HK 1027377 A1 HK1027377 A1 HK 1027377A1
Authority
HK
Hong Kong
Prior art keywords
nucleotidic
seq
code
sequences
lage
Prior art date
Application number
HK00106456A
Other languages
English (en)
Inventor
Frederic Triebel
Renato Mastrangeli
Sergio Romagnani
Original Assignee
Inst Nat Sante Rech Med
Roussy Inst Gustave
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Roussy Inst Gustave, Applied Research Systems filed Critical Inst Nat Sante Rech Med
Publication of HK1027377A1 publication Critical patent/HK1027377A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Mechanical Coupling Of Light Guides (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Fats And Perfumes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK00106456A 1997-06-18 2000-10-11 Lage-3 splice variants. HK1027377A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97401404A EP0900841A1 (en) 1997-06-18 1997-06-18 LAG-3 splice variants
PCT/EP1998/003307 WO1998058059A1 (en) 1997-06-18 1998-06-03 Lag-3 splice variants

Publications (1)

Publication Number Publication Date
HK1027377A1 true HK1027377A1 (en) 2001-01-12

Family

ID=8229784

Family Applications (1)

Application Number Title Priority Date Filing Date
HK00106456A HK1027377A1 (en) 1997-06-18 2000-10-11 Lage-3 splice variants.

Country Status (18)

Country Link
EP (2) EP0900841A1 (no)
JP (1) JP2002505582A (no)
KR (1) KR100552526B1 (no)
CN (1) CN1181201C (no)
AT (1) ATE274057T1 (no)
AU (1) AU740147B2 (no)
BR (1) BR9810925A (no)
CA (1) CA2293735A1 (no)
DE (1) DE69825741T2 (no)
DK (1) DK0977856T3 (no)
EA (1) EA003086B1 (no)
EE (1) EE04378B1 (no)
ES (1) ES2227862T3 (no)
HK (1) HK1027377A1 (no)
IL (2) IL133544A0 (no)
NO (1) NO996097L (no)
PT (1) PT977856E (no)
WO (1) WO1998058059A1 (no)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030100359A1 (en) * 2000-10-04 2003-05-29 Loose Timothy C. Audio network for gaming machines
EP1295895B1 (en) * 2001-09-19 2011-08-10 Institut Gustave Roussy Peptides and proteins binding to glu-pro motifs, therapeutical compositions containing the same and applications thereof
SE0103423D0 (sv) * 2001-10-12 2001-10-12 Astrazeneca Ab Polymorphism
CA2476518A1 (en) * 2002-02-22 2003-09-04 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US7364508B2 (en) 2003-01-16 2008-04-29 Wms Gaming, Inc. Gaming machine environment having controlled audio and visual media presentation
US7867085B2 (en) 2003-01-16 2011-01-11 Wms Gaming Inc. Gaming machine environment having controlled audio and visual media presentation
US7367886B2 (en) 2003-01-16 2008-05-06 Wms Gaming Inc. Gaming system with surround sound
US8313374B2 (en) 2003-02-14 2012-11-20 Wms Gaming Inc. Gaming machine having improved audio control architecture
AU2004217526B2 (en) 2003-02-28 2010-02-04 St. Jude Children's Research Hospital Inc. T cell regulation
FR2902101B1 (fr) * 2006-06-12 2012-12-28 Scras Peptides a activite anti-proliferative
US8172677B2 (en) 2006-11-10 2012-05-08 Wms Gaming Inc. Wagering games using multi-level gaming structure
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
EP3508502B1 (en) 2013-09-20 2023-04-26 Bristol-Myers Squibb Company Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
US9412222B2 (en) 2013-09-20 2016-08-09 Igt Coordinated gaming machine attract via gaming machine cameras
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
EP3116909B1 (en) 2014-03-14 2019-11-13 Novartis Ag Antibody molecules to lag-3 and uses thereof
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
IL297090A (en) 2015-07-30 2022-12-01 Macrogenics Inc Molecules that bind pd-1 and methods of using them
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
TWI758267B (zh) 2015-12-14 2022-03-21 美商宏觀基因股份有限公司 對於pd-1和ctla-4具有免疫反應性的雙特異性分子及其使用方法
RU2018123481A (ru) 2015-12-16 2020-01-20 Мерк Шарп И Доум Корп. Анти-lag3 антитела и антигенсвязывающие фрагменты
SG11201907208XA (en) 2017-02-10 2019-09-27 Regeneron Pharma Radiolabeled anti-lag3 antibodies for immuno-pet imaging
AU2018277824A1 (en) 2017-05-30 2019-10-17 Bristol-Myers Squibb Company Treatment of LAG-3 positive tumors
MX2019012076A (es) 2017-05-30 2019-12-09 Bristol Myers Squibb Co Composiciones que comprenden un anticuerpo anti gen-3 de activacion del linfocito (lag-3) o un anticuerpo anti-lag-3 y un anticuerpo anti muerte celular programada 1 (pd-1) o anti ligando 1 de muerte celular programada (pd-l1).
BR112021021713A2 (pt) 2019-05-13 2022-04-19 Regeneron Pharma Método de tratamento de câncer ou inibição do crescimento de um tumor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU616639B2 (en) * 1986-08-21 1991-11-07 Trustees Of Columbia University In The City Of New York, The Dna encoding the t cell surface protein t4 and use of fragments of t4 in the treatment of aids
FR2656800B1 (fr) * 1990-01-08 1992-05-15 Roussy Inst Gustave Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques.
DK0758383T3 (da) * 1994-05-06 2007-05-29 Roussy Inst Gustave Oplöselige polypeptidfraktioner af LAG-3-proteinet; fremgangsmåde til fremstilling; terapeutisk sammensætning; antiidiotypisk antistof

Also Published As

Publication number Publication date
EE9900581A (xx) 2000-08-15
EP0977856A1 (en) 2000-02-09
NO996097D0 (no) 1999-12-09
IL133544A (en) 2006-12-31
AU740147B2 (en) 2001-11-01
ATE274057T1 (de) 2004-09-15
WO1998058059A1 (en) 1998-12-23
DK0977856T3 (da) 2004-12-20
IL133544A0 (en) 2001-04-30
DE69825741D1 (de) 2004-09-23
NO996097L (no) 2000-02-17
KR100552526B1 (ko) 2006-02-14
CN1260833A (zh) 2000-07-19
CA2293735A1 (en) 1998-12-23
KR20010013539A (ko) 2001-02-26
PT977856E (pt) 2005-01-31
DE69825741T2 (de) 2005-09-01
CN1181201C (zh) 2004-12-22
EP0900841A1 (en) 1999-03-10
ES2227862T3 (es) 2005-04-01
AU8435598A (en) 1999-01-04
EP0977856B1 (en) 2004-08-18
JP2002505582A (ja) 2002-02-19
EA003086B1 (ru) 2002-12-26
EE04378B1 (xx) 2004-10-15
BR9810925A (pt) 2000-08-15
EA200000038A1 (ru) 2000-06-26

Similar Documents

Publication Publication Date Title
HK1027377A1 (en) Lage-3 splice variants.
AU7550098A (en) System for expressing hyperthermostable protein
EP1037999A4 (en) POLYPEPTIDES AND NUCLEOTIDES PORPHYROMONAS GINGIVALIS
CY1106978T1 (el) Ενζυμα φωσφοδιεστερασης
NZ508439A (en) Novel endometriosis-associated gene
DK0870833T3 (da) Gener for ultrathermostabile proteaser
EP1006126A3 (en) Osteogenic peptides
DE60015042D1 (de) Nukleotidsequenzen, welche für das dapF-Gen kodieren
EP0769553A4 (en) DNA FRAGMENT, RECOMBINANT VECTOR THAT CONTAINS IT AND METHOD FOR EXPRESSING FOREIGN GENES WITH ITS USE
ES2124694T3 (es) Clonacion de la n-metil-hidantoinasa.
AU7655994A (en) Cloning of a member of the serine-threonine-kinase family
HUP0001969A2 (hu) Az NNT-1 neurotróf faktor
SE9801098D0 (sv) Receptors
WO2000017232A3 (de) Regulatorisches protein aus humanen keratinozyten
EP0476670A3 (en) Cloned n-carbamoylsarcosine-amidohydrolase
DE60036676D1 (de) G-protein-gekoppelter rezeptor-ähnliche proteine
DE69831584D1 (de) Polypeptide mit wasserkanalaktivität und dna sequenzen
DE60021707D1 (de) Beta-primeverosidase gen
WO1999060117A3 (fr) Polypeptide prax-1
WO2000046367A3 (en) Proteins capable of triggering g2/m transition and of interacting with cdc2- and cyclin b

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20090603